QQ客服 官方微博 反馈留言

	The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
	Zhang JianZhong; Tsai Tsen-Fang; Lee Min-Geol; Zheng Min; Wang Gang; Jin HongZhong; Gu Jun; Li RuoYu; Liu QuanZhong; Chen Jin
	2017
卷号	88期号:1页码:36-45
关键词	Asia Efficacy Janus kinase inhibitor Plaque psoriasis Safety Tofacitinib
ISSN号	1873-569X
DOI	10.1016/j.jdermsci.2017.05.004
URL标识	查看原文
收录类别	PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6368240
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Zhang JianZhong,Tsai Tsen-Fang,Lee Min-Geol,et al. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study[J],2017,88(1):36-45.
APA	Zhang JianZhong.,Tsai Tsen-Fang.,Lee Min-Geol.,Zheng Min.,Wang Gang.,...&Crook Tim.(2017).The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.,88(1),36-45.
MLA	Zhang JianZhong,et al."The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study".88.1(2017):36-45.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。